Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on.
Washington, DC (PRWEB) April 10, 2023 The Society for RNA Therapeutics is pleased to announce the members of its charter board of directors. The mission of